{
    "organizations": [],
    "uuid": "eeb0d72433bb29697b94086693525c7ffa1c6b27",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hebei-changshan-biochemical-pharma/brief-hebei-changshan-biochemical-pharmaceutical-sees-fy-2018-q1-net-profit-could-rise-up-to-10-pct-idUSL4N1RH2YT",
    "ord_in_thread": 0,
    "title": "BRIEF-Hebei Changshan Biochemical Pharmaceutical sees FY 2018 Q1 net profit could rise up to 10 pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Hebei Changshan Biochemical Pharmaceutical Co Ltd\n* Says it sees FY 2018 Q1 net profit to increase by up to 10 percent, or to be 43 million yuan to 47.3 million yuan\n* Says FY 2017 Q1 net profit was 43 million yuan\n* Comments that increased income from heparin water needle preparation and heparin crude drug as main reasons for the forecast\nSource text in Chinese: goo.gl/i6xmtF\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-04-04T15:11:00.000+03:00",
    "crawled": "2018-04-05T17:21:26.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "hebei",
        "changshan",
        "biochemical",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "see",
        "fy",
        "q1",
        "net",
        "profit",
        "increase",
        "percent",
        "million",
        "yuan",
        "million",
        "yuan",
        "say",
        "fy",
        "q1",
        "net",
        "profit",
        "million",
        "yuan",
        "comment",
        "increased",
        "income",
        "heparin",
        "water",
        "needle",
        "preparation",
        "heparin",
        "crude",
        "drug",
        "main",
        "reason",
        "forecast",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}